Recruiting
Phase 2
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
About this study
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
- Condition
- Prostate Cancer
- Tested
- focal brachytherapy boost to SBRT
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Who can join
- Age
- Not specified
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 7
- Eligible sex: Male
- Study condition: Prostate Cancer
- Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
- ECOG 0-1
- Charlson Comorbidity Index ≤ 4
- Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.
- Exclusion - none
Where
2 sites, 2 recruiting
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
CHUQ
Québec, Quebec, Canada
Contact
-
Mom Phat
514-890-8254 mom.phat.chum@ssss.gouv.qc.ca
Potential match only. Final eligibility is determined by the study team.